AIRWAY CLEARANCE AIMS TO REDUCE PULMONARY EXACERBATIONS AND HOSPITALIZATIONS¹

FOR "AT-RISK" RESPIRATORY PATIENTS

HFCWO THER

COPD patients using high frequency chest wall oscillation (HFCWO) therapy have shown a reduced annualized hospitalization rate for respiratory causes and better overall respiratory health.¹

HFCWO HELPS COPD PATIENTS

- 24.9% increase in patients having no hospitalizations for respiratory causes compared to prior year¹
- 42% increase in favorable rating of vest therapy for "overall respiratory health"¹
- 54.4% reduction in annualized hospitalization rates¹
- 20.1% reduction in patients having 3 or more hospitalizations for respiratory causes compared to prior year¹

THE TYPICAL SYMPTOMS FOR CHRONIC AIRWAY DISEASES SUCH AS COPD, CHRONIC BRONCHITIS OR ASTHMA ARE SIMILAR AND CAN OVERLAP

An accurate and timely diagnosis provides at risk patients a better opportunity for positive health outcomes²

- 45% of COPD patients with a chronic cough have episodes of acute bronchitis/pneumonia³
- 42% of COPD patients may have Bronchiectasis⁴
 - "Airway clearance therapy is the most fundamental aspect for the treatment of bronchiectasis"⁵
 - "When sputum is coughed up, millions of bacteria are removed from the lungs"⁵
- Majority of COPD patients have hyperinflation of the lungs, resulting in diaphragmatic dysfunction^{6,7}



AIRWAY CLEARANCE AIMS TO REDUCE PULMONARY EXACERBATIONS AND HOSPITALIZATIONS⁷

- Patients hospitalized for COPD have a 30-day readmission rate of 22.6%, at a cost over \$15 billion^{8,9}
- 30-day readmission estimated at 17-25% for patients hospitalized for pneumonia, at a cost of \$10 billion¹⁰
- Early diagnosis and implementation of airway clearance can reduce morbidity and mortality¹¹



est

HOW SYMPTOMS LEAD TO APPROVED DIAGNOSIS FOR HECWO



AffloVest requires a doctor's prescription for treatment by High Frequency Chest Wall Oscillation (HFCWO). The AffloVest has received the FDA's 510k clearance for U.S. market availability, and is approved for Medicare, Medicaid, and private health insurance reimbursement under the Healthcare Common Procedure Coding System (HCPCS) code E0483 - High Frequency Chest Wall Oscillation. The AffloVest is also available through the U.S. Department of Veterans Affairs/Tricare. Patients must qualify to meet insurance eligibility requirements.

REFERENCES

- org/10.17226/21794
 3. Dahl, M. et al. Chronic Cough in Individuals with COPD: A Population based Cohort Study. CHEST COPD: Original Research. 2020; 157(6): 1446-1454.
 4. Kosmas, E. et. al. Bronchiectasis in Patients with COPD: An Irrelevant Imagery Finding of a Clinical Important Phenotype? CHEST. 2016; 150(4):894A.
 5. Flume, Patrick, M.D. "The Importance of Airway Clearance for Patients". NTM and Bronchiectasis Physician and Patient Conference. June 2019. https://www.youtube.com/watch?v=-bWftVARLRc&app=desktop
 6. Gagnon, P. et al. Pathogenesis of Hyperinflation in Chronic Obstructive Pulmonary Disease. International Journal of COPD. 2014; 9:187-201.
 7. McCool, F. et al. Dysfunction of the Diaphragm. N Engl J Med 2012;366:932-42.
 8. Portillo, E. et al. Reducing COPD Readmission Rates: Using a COPD Care Service During Care Transitions. Federal Practitioner. 2018; 35(11):30-36
 9. Press, V. et al. Insights about the Economic impact of COPD readmissions post implementation of the Hospital Readmission Reduction Program. Current Opinion Pulmonary Med. 2018 Mar; 24(2): 138-146.
 10. Weinreich, M. et al. Predicting the Risk of Readmission in Pneumonia: A Systematic Review of Model Performance. Annals of the American Thoracic Society. 2016; 13(9):1607-1614.
 11. Volsko, T. Airway Clearance Therapy: Engline the Evidence. Respireters Care. 2012, 52(10):110-22.
- 11. Volsko, T. Airway Clearance Therapy: Finding the Evidence. Respiratory Care. 2013; 58(10):1669-78

International Biophysics Corporation | 2101 E. St. Elmo Rd. Ste 275 | Austin, TX 78744 Afflo INTERNATIONAL (T) 888-711-1145 | (F) 888-793-2319 | afflovest.com | info@biophysicscorp.com BIOPHYSICS CORPORATION MKT0074 Rev A